1. Schmuhl E, et al. “Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK.” Biochem Pharmacol. 2014;87(3):489-501.
2. Devinsky O, et al. “Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.” Epilepsia. 2014;55(6):791-802.
3. Cherniakov I, et al. “Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.” J Control Release. 2017;266:1-7.
4. Ibid.
5. Huestis MA. “Human cannabinoid pharmacokinetics.’ Chem Biodivers. 2007;4(8):1770-1804.
6. Lee WS, et al. “Cannabidiol limits T cell-mediated chronic autoimmune myocarditis: Implication to autoimmune disorders and organ transplantation.” Mol Med. 2016;22:136-146.
7. Tomida I, et al. “Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.” J Glaucoma. 2006;15(5):349–353.
8. Shelef A, et al. “Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study.” J Alzheimer’s Dis. 2016;51(1):15-19.
9. Staiano RI, et al. “Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors.” J Leukoc Biol. 2016;99(4):531–540.
10. Downs D. “The science behind the DEA’s long war on marijuana.” Scientific American. April 19, 2016.
11. Ibid.
12. Salk News. “Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells.” June 27, 2016.
13. Abuhasira R, et al. “Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly.” Eur J intern Med. 2018;49:44-50.
14. Jadoon KA, et al. “A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.” JCI Insight. 2017;2(12):e93760.
15. Jadoon KA, et al. “A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.” JCI Insight. 2017;2(12):e93760.
16. Russo EB. “Cannabinoids in the management of difficult to treat pain.” Ther Clin Risk Manag. 2008;4(1):245-259.
17. Assaf S, et al. “Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study.” J Alzheimer’s Dis. 2016;51(1):15-19.
18. Rajan TS, et al. “Cannabidiol activates neuronal precursor genes in human gingival mesenchymal stromal cells.” J Cell Biochem. 2017;118(6):1531-1546.
19. Stith SS, et al. “Patient-reported symptom relief following medical cannabis consumption.” Front Pharmacol. 2018;9:916.
20. Rakavashisth TB, et al. “Decreased prevalence of diabetes in marijuana users: Cross-sectional data from the National Health and Nutrition Examination Surgery (NHANES) III.” BMJ Open. 2012;2:e000494.
21. Vigil JM, et al. “Effectiveness of raw, natural medical cannabis flower for treating insomnia under naturalistic conditions.” Medicines (Basel). 2018;5(3):75.
22. Corroon J and Phillips JA. “A cross-sectional study of cannabidiol users.” Cannabis Cannabinoid Res. 2018;3(1):152-161.
23. Jadoon KA, et al. “Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel group pilot study.” Diabetes Care. 2016;39(10):1777-1786.
24. Lee WS, et al. “Cannabidiol limits T cell-mediated chronic autoimmune myocarditis: Implication to autoimmune disorders and organ transplantation.” Mol Med. 2016;22:136-146.
25. Cherniakov I, et al. “Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.” J Control Release. 2017;266:1-7.
26. http://www.outwordmagazine.com/inside-outword/glbt-news/1266-survey-shows-low-acceptance-of-the-science-of-the-ecs-endocannabinoid-system
27. Sulak D. “Introduction to the endocannabinoid system.” Norml. 2015.
28. Benito C, Nuñez E, Tolon RM et al (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23: 11136–11141.
29. Kwok CH, et al. “Age-dependent plasticity in endocannabinoid modulation of pain processing through postnatal development.” Pain. 2017;158(11):2222-2232.
30. Ibid.
31. Russo EB. “Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?” Neuro Endocrinol Lett. 2004;25(1-2):31-39.
32. Jadoon KA, et al. “Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel group pilot study.” Diabetes Care. 2017;39(10):1777-1786.
33. Deisseroth K, et al. “Natural neural projection dynamics underlying social behavior.” Cell. 2014;157(7):1535-1551.
34. DiSalvo D. “Marijuana may be a weapon against brain aging, suggests new study.” Forbes. May 30, 2017.
35. Gorzo AB, et al. “A chronic low dose of Δ9 — tetrahydrocannabinol (THC) restores cognitive function in old mice.” Nature Med. 2017;23:782-787.
36. University of Bonn. “Vicious circle leads to loss of brain cells in old age.” Science Daily. August 31, 2018.
37. University of Bonn. “Vicious circle leads to loss of brain cells in old age.” Science Daily. August 31, 2018.
38. Ibid.
39. Szalavitz M. “How cannabinoids may slow brain aging.” TIME. Oct. 29, 2012.
40. Hughes C. “’A puff a day’ can keep Alzheimer’s away, says cannabis researcher.” Civilized. May 28, 2018.
41. Huestis MA. “Human cannabinoid pharmacokinetics.” Chem Biodivers. 2007;4(8):1770-1804.
42. United States Patent Hampson, et al. 6,630,507. “Cannabinoids as antioxidants and neuroprotectants.” USPTO Patent. October 7, 2003.
43. Norml. (2013, September 5). 25 years ago: DEA’s own administrative law judge ruled cannabis should be reclassified under federal law [Press release]. Retrieved from: http://norml.org/news/2013/09/05/25-years-ago-dea-s-own-administrative-law-judge-ruled-cannabis-should-be-reclassified-under-federal-law